Myriad Genetics — Third Quarter 2026 Earnings Summary

Myriad Genetics reported third-quarter 2026 revenue of $202.7 million, a 1% decrease year-over-year, driven by lower test volumes in its Prenatal Health segment which were partially offset by growth in the Cancer Care Continuum and Mental Health categories. On October 19, 2026, the company entered into a definitive agreement to sell its Prenatal Health business to Labcorp for $210 million in cash plus inventory value, a transaction expected to close by early 2027. The company raised its full-year 2026 revenue guidance midpoint to $785 million, reflecting strong execution in its core businesses and the anticipated impact of the strategic divestiture. Despite the revenue increase, the company reported a net loss of $43.9 million for the quarter due to higher operating expenses and lower gross margins.